Catalyst Event
Eli Lilly and Co (LLY) · Other
From KEDI Global Longevity Bio Index (KGLB)
3/19/2026, 12:00:00 AM
Eli Lilly announced positive topline results from the TRANSCEND-T2D-1 Phase 3 trial on March 19, 2026, showing its next-generation 'Triple-G' agonist, retatrutide, led to significant reductions in A1C and body weight.
Korean Translation
2026년 3월 19일, 차세대 'Triple-G' 작용제인 레타트루타이드가 제2형 당뇨병 성인 환자의 당화혈색소(A1C)와 체중을 유의미하게 감소시켰다는 TRANSCEND-T2D-1 3상 임상시험의 긍정적인 탑라인 결과를 발표함.
Related Recent Events
Biogen Inc (BIIB) · Other
FDA PDUFA action date for the supplemental Biologics License Application (sBLA) for a subcutaneous formulation of LEQEMBI is May 24, 2026; Medium importance is estimated due to uncertain market reaction scheduled.
5/24/2026, 12:00:00 AM
Amgen Inc (AMGN) · Other
A quarterly dividend of $2.52 per share for Q2 2026 is scheduled, with an ex-dividend date of May 15, 2026; a price impact of ≥1% is estimated due to the routine nature of the distribution, scheduled.
5/15/2026, 12:00:00 AM
Pfizer Inc (PFE) · Earnings Release
First quarter 2026 earnings release and conference call scheduled.
5/5/2026, 12:00:00 AM
Merck and Co Inc (MRK) · Earnings Release
Merck is scheduled to release its Q1 2026 financial results before the market opens. Earnings releases typically cause significant price volatility, justifying a Medium importance, scheduled.
4/30/2026, 12:00:00 AM
Bristol-Myers Squibb Co (BMY) · Earnings Release
First quarter 2026 financial results and conference call scheduled for 2026-04-30. Routine earnings announcements typically result in minor price fluctuations (Low importance) scheduled.
4/30/2026, 12:00:00 AM
Medpace Holdings Inc (MEDP) · Earnings Release
First quarter 2026 financial results to be reported after market close on April 22, 2026. Importance is estimated as High as earnings releases typically cause significant price volatility, scheduled.
4/22/2026, 12:00:00 AM